Un accès direct et non invasif à la pathogénèse par l’évaluation de biomarqueurs volatils (FeNO) ou non volatils de l’air exhalé grâce à la méthode des condensats de l’air exhalé (EBC) est utile pour estimer précocement le degré d’atteinte pulmonaire en rapport avec une exposition professionnelle et surveiller son évolution en regard des mesures correctives mises en place. L’étude du NO exhalé (FeNO) est actuellement bien standardisée et l’augmentation exponentielle des publications concernant les EBC reflètent un intérêt croissant pour le diagnostic non invasif des atteintes pulmonaires. Les marqueurs étudiés dans l’air exhalé sont des produits de l'inflammation tels que le FeNO et les cytokines ainsi que des produits du stress oxydant incluant le peroxyde d'hydrogène, les produits de peroxydation lipidique (8-isoprostane, malondialdehyde) et les oxydes d'azote (NOx). S’agissant d’une technique d’exploration relativement récente, les modalités méthodologiques font encore l’objet de nombreux travaux, les premières recommandations internationales étant apparues en 2005. Les écueils méthodologiques sont nombreux et encore décrits dans la littérature en 2012. Ils concernent toutes les étapes du processus du recueil et d’analyses.Objectifs : L’objectif principal de notre recherche était dans un premier temps de développer la méthode des EBC pour l'étude des composés de l'air exhalé puis de détecter et quantifier des biomarqueurs tels que les protéines totales, les NOx et le 8-isoprostane dans les EBC d’une population d’adultes sains (n= 48) ou atteints de pathologies pulmonaires telles que l'asthme (n=24), la BPCO (n=20), la pneumopathie interstitielle diffuse (n=27) et la sclérodermie (n=27). L’objectif secondaire était la comparaison des niveaux de biomarqueurs dosés dans les EBC et du FeNO chez les sujets malades par rapport aux témoins.Résultats / Conclusion : Notre recherche, soutenue l’ANR et l’ANSES, a permis de standardiser la méthodologie de recueil et d’analyse des EBC avec une optimisation du système de recueil et de l’agent coatant pour la détermination de la concentration nécessaire et compatible avec les analyses. Nous maitrisons le dosage dans les EBC des biomarqueurs tels que les protéines, les NOx et le 8-isoprostane. D'autres biomarqueurs sont encore en cours d'étude tels que le malondialdehyde et les cytokines. Ce travail méthodologique, publié, a permit dans un second temps la détection (> à 95%) et la quantification de ces biomarqueurs dans les EBC des sujets sains et malades de notre population.Perspectives : La constitution des valeurs de référence pour les biomarqueurs dosés dans les EBC est nécessaire à l’interprétation des dosages chez les sujets malades. Il convient également de finaliser la standardisation de la mesure des cytokines et du malondialdehyde et d’explorer de nouveaux biomarqueurs produits lors du stress nitrosant tels que la 3-nitrotyrosine pour compléter les mécanismes physiopathologiques. Enfin le développement de cette méthode non invasive et peu contraignante apparait prometteuse en clinique médicale dans le suivi individuel de la maladie ou son traitement comme lors d’études épidémiologiques respiratoires dans des populations exposées professionnellement ou environnementalement. Dans ce cadre, l’étude de marqueurs d’exposition professionnelle tels que les métaux lourds dans les EBC est en cours de développement. / The study of both volatile (FeNO) and non-volatile respiratory biomarkers using the method of exhaled breath condensates can be useful in medical surveillance of exposed workers, the early identification of respiratory diseases or in the monitoring of their development. Studies of exhaled NO (FeNO) is now well standardized and the exponential increase in publications on exhaled breath condensate (EBC) reflects growing interest in a non-invasive diagnosis of pulmonary diseases. The biomarkers studied are products of inflammation, such as FeNO and cytokines, and products of oxidative stress, including hydrogen peroxide (H202), products of lipid peroxydation (8-isoprostane, malondialdehyde) and nitrogen oxides. The first recommendation was published in 2005 but although many recent publications have applied this new method, numerous methodological pitfalls remain and still described in 2012. They concern all the stages of the collection to the analysis.Objectives: The main objective of this research was initially to develop the method of EBC for the study of compounds of exhaled air and then detect and quantify biomarkers such as total protein, NOx and 8-isoprostane in exhaled air in a population of healthy adults (n = 48) or patients with lung inflammatory diseases such as asthma (n = 24), COPD (n = 20), diffuse interstitial pneumonia (n = 27) and scleroderma (n = 27). The secondary objective was to compare levels of biomarkers measured in the EBC and FeNO in patients compared to controls.Results / conclusion: Our research, supported by ANR and ANSES, allowed to standardize the methodology of collection and analysis of EBC with a choice of the collection system and coating which must be effective and compatible with the analyzes. In EBC, we control the dosage of biomarkers such as proteins, NOx and 8-isoprostane. Other biomarkers are still being studied such as malondialdehyde and cytokines. This published methodological study, allowed in a second step the detection (> 95%) and quantification of these biomarkers in EBC of healthy patients in our population.Perspectives: This standardization is a key epidemiological requirement for the task force on the establishment of reference values and the publication of methodological guidelines so as to realize the promise of this approach for clinical studies of lung diseases. We have also to finish the development of biomarkers such as cytokines or malondialdehyde and to investigate new biomarkers to complete the pathophysiological mechanisms. Finally our objective is the widespread use of this noninvasive method in daily epidemiological studies on subjects with professional and/or environmental exposure. In this context, the study of markers of the toxic burden in the lungs such as heavy metals in the EBC is being developed.

Screening complex biological specimens such as exhaled air, tissue, blood and urine to identify biomarkers in different forms of cancer has become increasingly popular over the last decade, mainly due to new instruments and improved bioinformatics. However, despite some progress, the identification of biomarkers has shown to be a difficult task with few new biomarkers (excluding recent genetic markers) being considered for introduction to clinical analysis. This review describes recent advances in gas chromatographic methods for the identification of biomarkers in the detection, diagnosis and treatment of cancer. It presents a general overview of cancer metabolism, the current biomarkers used for cancer diagnosis and treatment, a background to metabolic changes in tumors, an overview of current GC methods, and collectively presents the scope and outlook of GC methods in oncology.

Background: Carbon monoxide (CO) is a toxic gas, but it is also produced endogenously when haem is degraded. When produced in vivo, CO is believed to have positive biological effects. For example it activates the production of cyclic guanosine mono-phosphate and causes vasodilatation. CO is also believed to have anti-inflammatory properties by binding to Mitogen activated protein (MAP) kinase. Several studies in cells, mice and rats support this opinion regarding both the circulatory as well as the anti-inflammatory properties. However, studies in larger animals regarding circulatory effects have demonstrated contradictory results. The only study in humans regarding anti-inflammatory properties of CO could not demonstrate such effects. Methods: This thesis consists of four different models. In paper I a method for analysis of CO in blood was developed using gas chromatography. In paper II a porcine model was used to investigate the elimination time for CO. The pigs in paper II had a high concentration of CO administered via blood, and CO concentrations were followed over time and kinetically parameters calculated. Circulatory parameters were also measured to evaluate if there were any circulatory changes after CO administration. In paper III CO´s anti-inflammatory properties were investigated in an endotoxin-induced systemic inflammatory model in pigs. Paper III was a randomized study where one group inhaled CO and the other group served as controls. Plasma cytokine concentrations were measured and followed over time as an indication of the inflammatory state. In paper IV, CO concentrations in blood from blood donors at the Blood Centre in Umeå were investigated. The blood donors also completed a questionnaire about age, smoking history and other possible sources for exogenous contamination of CO in the blood. Results and conclusions: In paper I we developed a method suitable for analysis of low concentrations of CO in blood. The half-life of CO at levels of 250 µM in pigs was found to be 60 minutes. CO did not show anti-inflammatory effects after an endotoxin-induced systemic inflammation in pigs. In banked blood CO was present at concentrations up to six times higher than normal concentrations. This could be a risk when transfusing such blood to susceptible patients.

Background: Measurement of carbon monoxide in expired air samples (ECO) is a non-invasive, cost-effective biochemical marker for smoking. Cut points of 6. ppm-10. ppm have been established, though appropriate cut-points for pregnant woman have been debated due to metabolic changes. This study assessed whether an ECO cut-point identifying at least 90% of pregnant smokers, and misidentifying fewer than 10% of non-smokers, could be established. Methods: Pregnant women (N=167) completed a validated self-report smoking assessment, a urine drug screen for cotinine (UDS), and provided an expired air sample twice during pregnancy. Results: Half of women reported non-smoking status early (51%) and late (53%) in pregnancy, confirmed by UDS. Using a traditional 8. ppm. +. cut-point for the early pregnancy reading, only 1% of non-smokers were incorrectly identified as smokers, but only 56% of all smokers, and 67% who smoked 5. + cigarettes in the previous 24. h, were identified. However, at 4. ppm. +, only 8% of non-smokers were misclassified as smokers, and 90% of all smokers and 96% who smoked 5. + cigarettes in the previous 24. h were identified. False positives were explained by heavy second hand smoke exposure and marijuana use. Results were similar for late pregnancy ECO, with ROC analysis revealing an area under the curve of 95 for early pregnancy, and 94 for late pregnancy readings. Conclusions: A lower 4. ppm ECO cut-point may be necessary to identify pregnant smokers using expired air samples, and this cut-point appears valid throughout pregnancy. Work is ongoing to validate findings in larger samples, but it appears if an appropriate cut-point is used, ECO is a valid method for determining smoking status in pregnancy.

Background: Measurement of carbon monoxide in expired air samples (ECO) is a non-invasive, cost-effective biochemical marker for smoking. Cut points of 6. ppm-10. ppm have been established, though appropriate cut-points for pregnant woman have been debated due to metabolic changes. This study assessed whether an ECO cut-point identifying at least 90% of pregnant smokers, and misidentifying fewer than 10% of non-smokers, could be established. Methods: Pregnant women (N=167) completed a validated self-report smoking assessment, a urine drug screen for cotinine (UDS), and provided an expired air sample twice during pregnancy. Results: Half of women reported non-smoking status early (51%) and late (53%) in pregnancy, confirmed by UDS. Using a traditional 8. ppm. +. cut-point for the early pregnancy reading, only 1% of non-smokers were incorrectly identified as smokers, but only 56% of all smokers, and 67% who smoked 5. + cigarettes in the previous 24. h, were identified. However, at 4. ppm. +, only 8% of non-smokers were misclassified as smokers, and 90% of all smokers and 96% who smoked 5. + cigarettes in the previous 24. h were identified. False positives were explained by heavy second hand smoke exposure and marijuana use. Results were similar for late pregnancy ECO, with ROC analysis revealing an area under the curve of 95 for early pregnancy, and 94 for late pregnancy readings. Conclusions: A lower 4. ppm ECO cut-point may be necessary to identify pregnant smokers using expired air samples, and this cut-point appears valid throughout pregnancy. Work is ongoing to validate findings in larger samples, but it appears if an appropriate cut-point is used, ECO is a valid method for determining smoking status in pregnancy.